Jefferies Financial Group initiated coverage on shares of Legend Biotech (NASDAQ:CALT) in a report issued on Tuesday, BenzingaRatingsTable reports. The firm issued a buy rating and a $44.00 target price on the stock. Jefferies Financial Group also issued estimates for Legend Biotech’s Q2 2020 earnings at ($0.40) EPS, Q3 2020 earnings at ($0.43) EPS, Q4 2020 earnings at ($0.66) EPS, FY2020 earnings at ($1.54) EPS, FY2021 earnings at $0.77 EPS, FY2022 earnings at $1.78 EPS, FY2023 earnings at $8.25 EPS and FY2024 earnings at $10.00 EPS.

Separately, Stifel Nicolaus initiated coverage on shares of Legend Biotech in a research report on Tuesday. They set a buy rating and a $28.00 price objective for the company.

Shares of Legend Biotech stock opened at $22.22 on Tuesday. Legend Biotech has a one year low of $19.00 and a one year high of $24.97.

About Legend Biotech

Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

See Also: What is the Dow Jones Industrial Average (DJIA)?

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.